Funder
U.S. Department of Health & Human Services | NIH | National Cancer Institute
Bayer
Publisher
Springer Science and Business Media LLC
Subject
Pathology and Forensic Medicine
Reference34 articles.
1. Food and Drug Administration. FDA approves an oncology drug that targets a key genetic driver of cancer, rather than a specific type of tumor. FDA news release. 2018.
https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm626710.htm
. Accessed 26 May 2019.
2. Drilon A, Laetsch TW, Kummar S, DuBois SG, Lassen UN, Demetri GD, et al. Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children. N Engl J Med. 2018;378:731–9.
3. Drilon A, Siena S, Ou SI, Patel M, Ahn MJ, Lee J, et al. Safety and antitumor activity of the multitargeted Pan-TRK, ROS1, and ALK inhibitor entrectinib: combined results from two phase I trials (ALKA-372-001 and STARTRK-1). Cancer Disco. 2017;7:400–9.
4. Vaishnavi A, Le AT, Doebele RC. TRKing down an old oncogene in a new era of targeted therapy. Cancer Disco. 2015;5:25–34.
5. Kheder ES, Hong DS. Emerging targeted therapy for tumors with NTRK fusion proteins. Clin Cancer Res. 2018;24:5807–14.
Cited by
409 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献